Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed A Othman

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
British Journal of Clinical Pharmacology|January 18, 2014
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsAhmed A Othman, Sandeep Dutta
Journal of Clinical Pharmacology|January 25, 2018
Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical TrialsAmit Khatri, Ahmed A Othman
Journal of Cardiac Surgery|January 25, 2021
Dynamic visceral ischemia in type A dissectionFrancesco Torella, Ahmed A Othman, Manoj Kuduvalli
Clinical Pharmacokinetics|September 22, 2019
Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus ErythematosusAhmed Nader, Mukul Minocha, Ahmed A Othman
Journal of Clinical Pharmacology|February 12, 2024
Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment StudiesIslam R Younis, Fan Wang, Ahmed A Othman
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2007
Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modelingAhmed A Othman, Amy Hauck Newman, Natalie D Eddington
Journal of Pharmaceutical Sciences|April 22, 2008
The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuseAhmed A Othman, Amy H Newman, Natalie D Eddington
Clinical Pharmacokinetics|October 28, 2017
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical TrialsBen Klünder, Mohamed-Eslam F Mohamed, Ahmed A Othman
Clinical Pharmacokinetics|December 24, 2019
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis IndicationMohamed-Eslam F Mohamed, Ben Klünder, Ahmed A Othman
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 21, 2016
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b StudyGeorge Haig, Deli Wang, Ahmed A Othman, et al.
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
British Journal of Clinical Pharmacology|January 18, 2014
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsAhmed A Othman, Sandeep Dutta
Journal of Clinical Pharmacology|January 25, 2018
Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical TrialsAmit Khatri, Ahmed A Othman
Journal of Cardiac Surgery|January 25, 2021
Dynamic visceral ischemia in type A dissectionFrancesco Torella, Ahmed A Othman, Manoj Kuduvalli
Clinical Pharmacokinetics|September 22, 2019
Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus ErythematosusAhmed Nader, Mukul Minocha, Ahmed A Othman
Journal of Clinical Pharmacology|February 12, 2024
Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment StudiesIslam R Younis, Fan Wang, Ahmed A Othman
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2007
Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modelingAhmed A Othman, Amy Hauck Newman, Natalie D Eddington
Journal of Pharmaceutical Sciences|April 22, 2008
The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuseAhmed A Othman, Amy H Newman, Natalie D Eddington
Clinical Pharmacokinetics|October 28, 2017
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical TrialsBen Klünder, Mohamed-Eslam F Mohamed, Ahmed A Othman
Clinical Pharmacokinetics|December 24, 2019
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis IndicationMohamed-Eslam F Mohamed, Ben Klünder, Ahmed A Othman
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 21, 2016
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b StudyGeorge Haig, Deli Wang, Ahmed A Othman, et al.
Pageof 12